Long term side effects of adjuvant chemotherapy in patients with early breast cancer

Breast

Volumn 24, Issue , 2015, Pages S149-S153

  Tao, Jessica J ^a   Visvanathan, Kala ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Cancer; Therapy; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPTORELIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ALOPECIA; AMENORRHEA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CYTOPENIA; DISEASE FREE SURVIVAL; EARLY MENOPAUSE; FATIGUE; FEMALE INFERTILITY; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL PAIN; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; OVARIECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECOND CANCER; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CARDIOTOXICITY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MENOPAUSE; MYELOID LEUKEMIA; NEUROTOXICITY SYNDROMES; OVARY; TIME FACTOR;

AMENORRHEA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LEUKEMIA, MYELOID; MENOPAUSE; NEUROTOXICITY SYNDROMES; OVARY; QUALITY OF LIFE; TIME FACTORS;

EID: 84948655314     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.07.035     Document Type: Article

References (51)

1. Early Breast Cancer Trialists' Collaborative G, Peto R., Davies C., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
2. Fisher B., Dignam J., Tan-Chiu E., et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001, 93:112-120.
3. Fisher B., Jeong J.H., Dignam J., et al. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001, 62-66.
4. Muss H.B. Adjuvant chemotherapy in older women with breast cancer: who and what?. J Clin Oncol 2014, 32:1996-2000.
5. Wolff A.C., Blackford A.L., Visvanathan K., et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 2015, 33:340-348.
6. Hammond M.E., Hayes D.F., Dowsett M., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
7. Wolff A.C., Hammond M.E., Hicks D.G., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013, 31:3997-4013.
8. Wolff A.C., Hammond M.E., Hicks D.G., et al. Reply to E.A. Rakha et al. J Clin Oncol 2015, 33:1302-1304.
9. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast Cancer. N Engl J Med 2005, 353:1784-1792.
10. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute. , based on November 2012 SEER data submission, posted to the SEER web site, April 2013. http://seer.cancer.gov/csr/1975_2010/.
11. DeSantis C.E., Lin C.C., Mariotto A.B., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014, 64:252-271.
12. Anderson G.F., Chu E. Expanding priorities - confronting chronic disease in countries with low income. N Engl J Med 2007, 356:209-211.
13. Allemani C., Weir H.K., Carreira H., et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2014, 385:977-1010.
14. Bray F., Ren J.S., Masuyer E., et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132:1133-1145.
15. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide 2013, IARC CancerBase No. 11 [Internet] Available from:, [accessed on 14 March 2015]. http://globocan.iarc.fr.
16. Ravdin P.M., Siminoff I.A., Harvey J.A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998, 16:515-521.
17. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710.
18. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
19. Romond E.H., Jeong J.-H., Rastogi P., et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:3792-3799.
20. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl J Med 2011, 365:1273-1283.
21. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001, 19:37-43.
22. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigattors. N Engl J Med 1992, 327:685-691.
23. Doyle J.J., Neugut A.I., Jacobson J.S., et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005, 23:8597-8605.
24. Pinder M.C., Duan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
25. Bardia A., Arieas E.T., Zhang Z., et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012, 131:907-914.
26. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
27. Schneider B.P., Zhao F., Wang M., et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012, 30:3051-3057.
28. Hershman D.L., Lacchetti C., Dworkin R.H., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of clinical Oncology clinical practice guideline. J Clin Oncol 2014, 32:1941-1967.
29. Brezden C.B., Phillips K.-A., Abdolell M., et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000, 18:2695-2701.
30. Wefel J.S., Vardy J., Ahles T., et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011, 12:703-708.
31. Chan R.J., McCarthy A.L., Devenish J., et al. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer 2015, 51:437-450.
32. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment - associated cognitive change: an update on the state of the science. J Clin Oncol 2012, 30:3675-3686.
33. Smith R.E. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer 2003, 4:273-279.
34. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24:1045-1051.
35. Del Mastro L., Boni L., Michelotti A., et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011, 306:269-276.
36. Moore H.C., Unger J.M., Phillips K.A., et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015, 372:923-932.
37. Smith I.E., Dowsett M., Yap Y.-S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006, 24:2444-2447.
38. Partridge A., Gelber S., Gelber R.D., et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007, 43:1646-1653.
39. Parker W.H., Feskanich D., Broder M.S., et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013, 121:709-716.
40. McCarthy A.M., Menke A., Ouyang P., et al. Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older. Cancer Prev Res Phila 2012, 5:847-854.
41. McCarthy A., Visvanathan K. Oophorectomy is associated with a higher prevalence of arthritis and lower bone mineral density in women 40 years and older (Abstract P4-11-01). San Antonio breast cancer symposium 2011.
42. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-107.
43. Wolff A.C., Davidson N.E. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. J Clin Oncol 2006, 24:4949-4951.
44. Francis P.A., Regan M.M., Fleming G.F., et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015, 372:436-446.
45. Pagani O., Regan M.M., Walley B.A., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014, 371:107-118.
46. International Breast Cancer Study G, Castiglione-Gertsch M., O'Neill A., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003, 95:1833-1846.
47. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
48. Wolff A.C., Abeloff M.D. Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so. J Natl Cancer Inst 2002, 94:1041-1043.
49. Curigliano G., Viale G., Bagnardi V., et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699.
50. Tolaney S.M., Barry W.T., Dang C.T., et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015, 372:134-141.
51. Gradishar W.J., Anderson B.O., Blair S.L., et al. Breast cancer version 3.2014. J Natl Compr Cancer Netw 2014, 12:542-590.